Assessing achievement and maintenance of glycemic control by patients initiating basal insulin

Current Medical Research and Opinion

Volumn 28, Issue 10, 2012, Pages 1647-1656

  Wu, Ning ^a   Aagren, Mark ^b   Boulanger, Luke ^a   Friedman, Michelle ^a   Wilkey, Kelly ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Achievement of glycemic control; Basal insulin initiation; Non sustained glycemic control; Patient characteristics

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BASAL INSULIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84867867691     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.722989     Document Type: Article

References (17)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011
2. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570-81 (Pubitemid 34517204)
3. Riddle MC. Glycemic control and cardiovascular mortality. Curr Opin Endocrinol Diabetes Obes 2011;18:104-9
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203
6. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59
7. Borah BJ, Darkow T, Bouchard J, et al. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clin Ther 2009;31:623-31
8. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18 (2):CD005613
9. Gordon J, Pockett RD, Tetlow AP, et al. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study. Int J Clin Pract 2010;64:1609-18
10. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9 (Pubitemid 41587600)
11. Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; 7:CD006383
12. Heintjes EM, Thomsen TL, Penning-van Beest FJ, et al. Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther 2010;27:211-22
13. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20 (Pubitemid 351160234)
14. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008;25:924-32
15. Tapp RJ, Shaw JE, Zimmet PZ, et al. Albuminuria is evident in the early stages of diabetes onset: results from the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Am J Kidney Dis 2004;44:792-8 (Pubitemid 39445910)
16. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47:1703-20
17. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53